INNOVATIVE PATIENT CARE: ADVANCING HUMAN-CENTRIC TREATMENTS THROUGH THE SNAP TRIAL

 

THE SNAP TRIAL

The SNAP trial aims to improve treatment outcomes for patients with Staphylococcus aureus bloodstream infections. The study currently includes sites in Australia, New Zealand, Singapore, Canada and Israel.

REPORT

Primary Outcome: To identify the most effective treatments for Staphylococcus aureus bloodstream infection.

CASE STUDY

“We’re excited to be conducting SNAP with the aim to improve the treatment of Staph Aureus bloodstream infections”

STEVEN TONG, SNAP CHIEF INVESTIGATOR

LATEST MILESTONE

100 children now randomised into the SNAP randomised platform, now up to 104. Based on randomisations, SNAP-PY is now the largest RCT involving children with S. aureus bacteraemia with 182 randomisations to date.

BACKGROUND

  • Every year, about 5000 patients in Australia develop a bloodstream infection due to Staphylococcus aureus (golden staph). Approximately 20 per cent will die within 30 days and each person requires a minimum of two weeks of intravenous antibiotics.

  • The Staphylococcus aureus Network Adaptive Platform trial (SNAP) aims to improve treatments for Staph aureus bloodstream infections. SNAP will involve more than 60 hospitals around the world and aims to recruit 6000 patients with Staph aureus bloodstream infections.

  • As the largest trial for Staph aureus bloodstream infections (the largest so far included 750 patients), SNAP will address multiple questions in parallel including what are the best initial antibiotics to use, whether adjunctive therapy is beneficial, and whether intravenous antibiotic therapy can be safely switched to oral therapy.

TRIAL DESIGN

  • Recruitment to the trial will commence in February 2022

  • SNAP is a pragmatic trial that facilitates broad involvement and includes many University of Melbourne affiliated hospitals as trial sites including a range of principal referral hospitals as well as regional hospitals.

  • In addition, specific patient populations that are often excluded from such trials are eligible for the study. These include children, pregnant women, and people who inject drugs.

KEY CONNECTIONS

  • Our Spiral Project Lead and EDC Platform manager for the SNAP Study is Emma Winks

    As a Project Manager at Spiral, Emma oversees software development used in clinical trials. She is used to working with lots of moving parts with a laser-beam focus.

  • “It is easy to get caught up in the emotions of this role but at the same time, it is incredibly rewarding.”

    MEET EMMA